| Rachael Nielsen, APRN | |
|
450 E 23rd St, Fremont, NE 68025-2303 | |
| (402) 721-1610 | |
| Not Available |
| Full Name | Rachael Nielsen |
|---|---|
| Gender | Female |
| Speciality | Nurse Practitioner |
| Experience | 10 Years |
| Location | 450 E 23rd St, Fremont, Nebraska |
| Accepts Medicare Assignments | Yes. She accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1386043453 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 363LA2100X | Nurse Practitioner - Acute Care | 111718 (Nebraska) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Methodist Fremont Health | Fremont, NE | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Physicians Clinic Inc | 4880506062 | 497 |
News Archive
There is a lesson in this unexpected juxtaposition nevertheless: No nation can safely base its tax and spending plans on inflexible commitments. Political life, both domestic and international, is too unpredictable. Yet U.S. government spending is mostly on autopilot. The government is scheduled to lay out $3.8 trillion this fiscal year -; 70 percent of which will go to mandatory-spending programs, chiefly Social Security, Medicare, Medicaid and interest on the federal debt. Mr. Obama's plan for fiscal 2015 does not change this; it would increase overall spending slightly, paying for it with selected tax increases, while shifting money among priorities here and there. But these tweaks would take place within the same 30 percent of discretionary spending that the current budget contains (3/4).
College of Science associate professor and researcher David Feliciano has received a $667,000 grant from the Department of Defense to explore the cellular underpinnings of Tuberous Sclerosis Complex (TSC), a developmental disorder characterized by the growth of benign tumors throughout the body, most notably in the brain.
OncoSec Medical Inc., a company developing the advanced-stage OncoSec Medical System (OMS) ElectroOncology therapies to treat solid tumors, announces it has established the University of California San Francisco (UCSF) as the second enrolling site for its Phase II Merkel cell carcinoma clinical trial (OMS-I110).
Today, the U.S. Food and Drug Administration approved Nexviazyme (avalglucosidase alfa-ngpt) for intravenous infusion to treat patients 1 year of age and older with late-onset Pompe disease.
› Verified 3 days ago
| Entity Name | Physicians Clinic Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1821049156 PECOS PAC ID: 4880506062 Enrollment ID: O20031105000345 |
News Archive
There is a lesson in this unexpected juxtaposition nevertheless: No nation can safely base its tax and spending plans on inflexible commitments. Political life, both domestic and international, is too unpredictable. Yet U.S. government spending is mostly on autopilot. The government is scheduled to lay out $3.8 trillion this fiscal year -; 70 percent of which will go to mandatory-spending programs, chiefly Social Security, Medicare, Medicaid and interest on the federal debt. Mr. Obama's plan for fiscal 2015 does not change this; it would increase overall spending slightly, paying for it with selected tax increases, while shifting money among priorities here and there. But these tweaks would take place within the same 30 percent of discretionary spending that the current budget contains (3/4).
College of Science associate professor and researcher David Feliciano has received a $667,000 grant from the Department of Defense to explore the cellular underpinnings of Tuberous Sclerosis Complex (TSC), a developmental disorder characterized by the growth of benign tumors throughout the body, most notably in the brain.
OncoSec Medical Inc., a company developing the advanced-stage OncoSec Medical System (OMS) ElectroOncology therapies to treat solid tumors, announces it has established the University of California San Francisco (UCSF) as the second enrolling site for its Phase II Merkel cell carcinoma clinical trial (OMS-I110).
Today, the U.S. Food and Drug Administration approved Nexviazyme (avalglucosidase alfa-ngpt) for intravenous infusion to treat patients 1 year of age and older with late-onset Pompe disease.
› Verified 3 days ago
| Entity Name | Methodist Fremont Health |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1235618216 PECOS PAC ID: 7911258520 Enrollment ID: O20181017000110 |
News Archive
There is a lesson in this unexpected juxtaposition nevertheless: No nation can safely base its tax and spending plans on inflexible commitments. Political life, both domestic and international, is too unpredictable. Yet U.S. government spending is mostly on autopilot. The government is scheduled to lay out $3.8 trillion this fiscal year -; 70 percent of which will go to mandatory-spending programs, chiefly Social Security, Medicare, Medicaid and interest on the federal debt. Mr. Obama's plan for fiscal 2015 does not change this; it would increase overall spending slightly, paying for it with selected tax increases, while shifting money among priorities here and there. But these tweaks would take place within the same 30 percent of discretionary spending that the current budget contains (3/4).
College of Science associate professor and researcher David Feliciano has received a $667,000 grant from the Department of Defense to explore the cellular underpinnings of Tuberous Sclerosis Complex (TSC), a developmental disorder characterized by the growth of benign tumors throughout the body, most notably in the brain.
OncoSec Medical Inc., a company developing the advanced-stage OncoSec Medical System (OMS) ElectroOncology therapies to treat solid tumors, announces it has established the University of California San Francisco (UCSF) as the second enrolling site for its Phase II Merkel cell carcinoma clinical trial (OMS-I110).
Today, the U.S. Food and Drug Administration approved Nexviazyme (avalglucosidase alfa-ngpt) for intravenous infusion to treat patients 1 year of age and older with late-onset Pompe disease.
› Verified 3 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Rachael Nielsen, APRN 450 E 23rd St, Fremont, NE 68025-2303 Ph: () - | Rachael Nielsen, APRN 450 E 23rd St, Fremont, NE 68025-2303 Ph: (402) 721-1610 |
News Archive
There is a lesson in this unexpected juxtaposition nevertheless: No nation can safely base its tax and spending plans on inflexible commitments. Political life, both domestic and international, is too unpredictable. Yet U.S. government spending is mostly on autopilot. The government is scheduled to lay out $3.8 trillion this fiscal year -; 70 percent of which will go to mandatory-spending programs, chiefly Social Security, Medicare, Medicaid and interest on the federal debt. Mr. Obama's plan for fiscal 2015 does not change this; it would increase overall spending slightly, paying for it with selected tax increases, while shifting money among priorities here and there. But these tweaks would take place within the same 30 percent of discretionary spending that the current budget contains (3/4).
College of Science associate professor and researcher David Feliciano has received a $667,000 grant from the Department of Defense to explore the cellular underpinnings of Tuberous Sclerosis Complex (TSC), a developmental disorder characterized by the growth of benign tumors throughout the body, most notably in the brain.
OncoSec Medical Inc., a company developing the advanced-stage OncoSec Medical System (OMS) ElectroOncology therapies to treat solid tumors, announces it has established the University of California San Francisco (UCSF) as the second enrolling site for its Phase II Merkel cell carcinoma clinical trial (OMS-I110).
Today, the U.S. Food and Drug Administration approved Nexviazyme (avalglucosidase alfa-ngpt) for intravenous infusion to treat patients 1 year of age and older with late-onset Pompe disease.
› Verified 3 days ago
Emily Nicole Johnson, APRN Nurse Practitioner Medicare: Not Enrolled in Medicare Practice Location: 750 E 29th St, Fremont, NE 68025 Phone: 402-753-2900 | |
Claire Montoya, DNP Nurse Practitioner Medicare: Medicare Enrolled Practice Location: 350 W 23rd St, Fremont, NE 68025 Phone: 402-721-7077 Fax: 402-721-7324 | |
Zachary Beerman, APRN (PMHNP) Nurse Practitioner Medicare: Accepting Medicare Assignments Practice Location: 2560 N Healthy Way, Fremont, NE 68025 Phone: 402-941-7245 | |
Mrs. Kimberly D Mueller, Nurse Practitioner Medicare: Medicare Enrolled Practice Location: 1240 E 23rd St, Fremont, NE 68025 Phone: 402-815-9741 | |
Amanda Nicole Esterling, APRN Nurse Practitioner Medicare: Not Enrolled in Medicare Practice Location: 220 E 22nd St, Fremont, NE 68025 Phone: 402-727-5500 Fax: 402-727-6047 | |
Megan Grote, APRN Nurse Practitioner Medicare: Accepting Medicare Assignments Practice Location: 450 E 23rd St, Fremont, NE 68025 Phone: 402-941-7030 Fax: 402-941-7032 | |
Amber Christine Juricek, DNP, FNP-C Nurse Practitioner Medicare: Accepting Medicare Assignments Practice Location: 680 E Fremont Medical Park Dr, Fremont, NE 68025 Phone: 402-727-1091 |